Insider · CIK 0001849061
Stephen Mayo
Files at MRK (Merck & Co., Inc.), SRPT (Sarepta Therapeutics, Inc.), ALLO (Allogene Therapeutics, Inc.). First filing Mar 6, 2024, latest Mar 13, 2026.
In brief
Stephen Mayo files SEC Form 4 as director at SRPT (Sarepta Therapeutics, Inc.), and also at MRK (Merck & Co., Inc.), ALLO (Allogene Therapeutics, Inc.). Since Mar 6, 2024, Stephen Mayo has reported 0 open-market buys worth $0 and 2 open-market sells worth $509k, the latest filed on Mar 13, 2026.
A track record needs three past buys with six months of prices behind them; Stephen Mayo has 0, so none is measured yet.
The newest scored trade: sold $123k of SRPT on Mar 12, 2026, filed Mar 13, 2026, scored 45 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $123k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SRPT: Sarepta Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | $123k 7,239 shares | -80% | +43% from low-83% from high | |
| 56Moderate | Sarepta Therapeutics, Inc. | $385k 3,135 shares | -32% | +83% from low-22% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 12, 2026 | SRPT SAREPTA THERAPEUTICS, INC. | 7,239 0.01% of outstanding | $123k | Mar 12, 2026 | none |
| Mar 5, 2024 | SRPT Sarepta Therapeutics, Inc. | 3,135 0.00% of outstanding | $385k | Mar 5, 2024 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | ALLO Allogene Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +144,400 | $0.00 | $0 | 144,400 | Jun 23, 2026 |
| Jun 4, 2026 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +16,875 | - | - | 18,640 | Jun 5, 2026 |
| May 29, 2026 | MRK Merck & Co., Inc. | AGrant or award Phantom Stockderivative | +1,853 | $118.72 | $220k | 14,825 | Jun 2, 2026 |
| Mar 12, 2026 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock | -7,239 | $17.02 | $123k | 1,765 | Mar 13, 2026 |
| Jun 18, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| May 30, 2025 | MRK Merck & Co., Inc. | AGrant or award Phantom Stockderivative | +2,863 | $76.84 | $220k | 12,540 | Jun 3, 2025 |
| Mar 5, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock | -3,135 | $122.96 | $385k | 6,621 | Mar 6, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +1,846 | $0.00 | $0 | 9,756 | Mar 5, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +3,679 | $0.00 | $0 | 3,679 | Mar 5, 2024 |
Questions about Stephen Mayo
Answered from the filings on this page, as of the latest one.
Is Stephen Mayo buying or selling?
In the last 12 months Stephen Mayo reported 0 open-market buys worth $0 and 1 open-market sell worth $123k on SEC Form 4; the latest was sold $123k of SRPT on Mar 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Stephen Mayo's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stephen Mayo has 0.
Where does Stephen Mayo file Form 4?
Stephen Mayo has filed Form 4 at SRPT (Sarepta Therapeutics, Inc.); MRK (Merck & Co., Inc.); ALLO (Allogene Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.